Eddy Yang
University of Alabama at Birmingham
H-index: 47
North America-United States
Top articles of Eddy Yang
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Olaparib in Patients With Pancreatic Cancer With BRCA1/2 Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study | JCO Precision Oncology | Eugene R Ahn Michael Rothe Pam K Mangat Elizabeth Garrett-Mayer Carmen J Calfa | 2024/2 |
A Novel Translational PET Imaging Approach to Quantifying Distal Tumor Immune Activation After Targeted Radiation Therapy and Checkpoint Blockade | International Journal of Radiation Oncology* Biology* Physics | Yujun Zhang Jessy S Deshane Eddy S Yang Benjamin Larimer | 2024/1/9 |
A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer | Breast Cancer Research and Treatment | Christos Vaklavas Erica M Stringer-Reasor Ahmed M Elkhanany Kevin J Ryan Yufeng Li | 2023/4 |
Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit | Communications medicine | Scott A Tomlins Nickolay A Khazanov Benjamin J Bulen Daniel H Hovelson Melissa J Shreve | 2023/2/7 |
Pertuzumab plus trastuzumab (P+ T) in patients (pts) with biliary tract cancer (BTC) with ERBB2/3 amplification (amp), overexpression (oe), or mutation (mut): Results from the … | Timothy Lewis Cannon Michael Rothe Elizabeth Garrett-Mayer Vi Kien Chiu Jimmy J Hwang | 2023/2/1 | |
Selective suppression of melanoma lacking IFN-γ pathway by JAK inhibition depends on T cells and host TNF signaling | Cancer Research | Hongxing Shen Fengyuan Huang Xiangmin Zhang Oluwagbemiga A Ojo Yuebin Li | 2023/4/4 |
Two novel stereotactic radiotherapy methods for locally advanced, previously irradiated head and neck cancers patients | Medical Dosimetry | Damodar Pokhrel Josh Misa Shane McCarthy Eddy S Yang | 2023/10/20 |
Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: 5-Year Toxicity and Biochemical Recurrence Results From a Prospective Trial | Advances in Radiation Oncology | Andrew M McDonald Michael C Dobelbower Eddy S Yang Grant M Clark Rojymon Jacob | 2019/1/1 |
Abstract PD17-01: Genomic analysis of circulating tumor DNA (ctDNA) from patients with HR+, HER2-mutant metastatic breast cancer (MBC) enrolled in SUMMIT: mechanisms of … | Cancer Research | Cynthia Ma James Waisman Adam M Brufsky Eddy S Yang Hans Wildiers | 2023/3/1 |
Combination Therapy with Trastuzumab and Niraparib: Quantifying Early Proliferative Alterations in HER2+ Breast Cancer Models | Biomedicines | Ameer Mansur Patrick N Song Yun Lu Andrew C Burns Luke Sligh | 2023/7/25 |
Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study | JCO Precision Oncology | Eddy S Yang Susan Halabi Michael Rothe Elizabeth Garrett-Mayer Pam K Mangat | 2023/2 |
Therapeutic targeting of DNA damage repair in the era of precision oncology and immune checkpoint inhibitors | Curtis A Clark Eddy S Yang | 2023/2/1 | |
Body composition and mortality in men receiving prostate radiotherapy: a pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126 | Cancer | Andrew M McDonald Lyudmila DeMora Eddy S Yang John M Hoyle Andrew Lenzie | 2023/3/1 |
Tumor Cell-Intrinsic PD-L1 Effects on Radiation-Induced Locoregional Antitumor Immunity | International Journal of Radiation Oncology, Biology, Physics | CA Clark Z Zhang Y Zhang C Xing B Larimer | 2023/10/1 |
An assessment of the feasibility and utility of an ACCC-ASCO implicit bias training program to enhance racial and ethnic diversity in cancer clinical trials | JCO Oncology Practice | Nadine J Barrett Leigh Boehmer Janelle Schrag Al B Benson III Sybil Green | 2023/4 |
Olaparib (O) in patients (pts) with colorectal cancer (CRC) with ATM mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. | Deepti Behl Michael Rothe Pam K Mangat Elizabeth Garrett-Mayer Laura Catherine Farrington | 2023/2/1 | |
Phase I study of niraparib in combination with radium-223 for the treatment of metastatic castrate-resistant prostate cancer | Clinical Cancer Research | Zachary Quinn Benjamin Leiby Guru Sonpavde Atish D Choudhury Christopher Sweeney | 2023/1/4 |
Validation of Immunotherapy Response Score as predictive of pan-solid tumor anti-PD-1/PD-L1 benefit | Cancer Research Communications | Benjamin J Bulen Nickolay A Khazanov Daniel H Hovelson Laura E Lamb Marc Matrana | 2023/7/25 |
Neratinib+ fulvestrant+ trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial | Annals of Oncology | K Jhaveri Lisa Diamond Eli H Wildiers Sara Alsterlind Hurvitz A Guerrero-Zotano | 2023/10/1 |
Phase II study of Afatinib in patients with tumors with human epidermal growth factor receptor 2–activating mutations: Results from the National Cancer Institute–molecular … | JCO Precision Oncology | Philippe L Bedard Shuli Li Kari B Wisinski Eddy S Yang Sewanti A Limaye | 2022/8 |
